Press Release

Newton, Mass. (April 28, 2010) -- Pro-Pharmaceuticals, Inc. (OTC: PRWP), a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that its management met with Colombia’s President Alvaro Uribe and the country’s Vice-Minister of Health, Carlos Cuervo Valencia at the Presidential Palace in Bogota last week. Pro-Pharmaceuticals was joined by executives from its Colombian marketing and distribution partner, PROCAPS S.A., to further demonstrate their commitment to improving the experience and results of chemotherapy treatment, through the use of DAVANAT®.

Pro-Pharmaceuticals’ senior management traveled to Colombia to expand on a meeting held in their Newton office in early April with Dr. Carlos Rada, Director of the Colombian National Cancer Institute (Instituto Nacional de Cancerologia), in which they discussed Pro-Pharmaceuticals’ unique polysaccharide technology, the improvement that DAVANAT® will bring to the quality of life for cancer patients in Colombia and the approval process for DAVANAT®. In Colombia, Pro-Pharmaceuticals continued to work on the approval process by visiting their partners PROCAPS S.A., as well as meeting with Colombia’s leading policy makers in Barranquilla, to address the advantages of DAVANAT® and the positive social impacts of having an inexpensive treatment for colorectal cancer.


“The meetings in Colombia went extremely well,” said Theodore D. Zucconi, Ph.D., Chief Executive Officer, Pro-Pharmaceuticals. “The goal of this joint project is to provide a social benefit for patients in Colombia by offering them a cost effective and compassionate treatment that fits within the guidelines of the National Healthcare System. It allows patients to receive chemotherapy while reducing suffering and side effects, significantly improving their quality of life. Furthermore, we believe that the Colombian healthcare system has advanced beyond those in the region and that Colombia is the ideal country to change the way cancer is treated throughout Latin America. Pro-Pharmaceuticals firmly supports the pending free trade agreement and the partnership has the potential to create a true Trans-American business that positions our partners in Colombia as the keystone of the Latin American initiative.”

According to the World Health Organization, 24,000 Colombians were diagnosed with colorectal cancer in 2007. More than 150,000 people in the countries having reciprocal agreements for approval with Colombia, have colorectal cancer.


“PROCAPS is pleased with the relationships that have been forged between Pro-Pharmaceuticals, PROCAPS, and the leading health officials of Colombia,” said Ruben Minski, President of PROCAPS S.A. “Through our manufacturing and marketing expertise, we will deliver to Colombian physicians and cancer patients a new treatment option in DAVANAT® that we believe will improve the patients’ experience with chemotherapy. This is especially significant to those thousands of patients who may not be able to afford other current cancer treatments.”


Clinical trial results for late-stage colorectal cancer patients demonstrate that when DAVANAT® is co-administered with the chemotherapy drug 5-FU, survival increased by 46 percent over the best standard of care and significantly reduced serious adverse events associated with chemotherapy.

About DAVANAT®

DAVANAT®, the Company's lead product candidate, is a polysaccharide polymer that targets Galectin receptors on cancer cells. Peer-reviewed studies have demonstrated that Galectins affect cell development and play important enabling roles in cancer, including tumor cell survival, angiogenesis, tumor metastasis and give the tumor the ability to evade the immune system. To date, DAVANAT® has been administered to approximately 100 cancer patients. Data from a clinical trial for end-stage colorectal cancer patients showed that DAVANAT® in combination with 5-FU extended median survival 46% longer than the best standard of care as determined by the patients’ physicians. Clinical trial results also showed that patients experienced substantially fewer serious adverse side effects from the chemotherapy including 100% elimination of serious Mucositis sores in the mouth and throughout the colon, resulting in less hospitalization, and greatly enhanced quality of life.

Pro-Pharmaceuticals, Inc.

Pro-Pharmaceuticals, OTCBB: PRWP, is a leader in the field of Galectin therapeutics and is engaged in the discovery, development and commercialization of therapeutics that target Galectin receptors for advanced treatment of cancer and fibrosis. Initially, the product pipeline is focused on increasing the efficacy and decreasing the toxicity of chemotherapy drugs. The Company is headquartered in Newton, Mass. Additional information is available at www.pro-pharmaceuticals.com.

About PROCAPS S.A.

PROCAPS S.A. is a pharmaceutical manufacturing and distribution company located in Barranquilla, Colombia. The company was established in 1977 and it has become a pioneer soft gelatin capsule manufacturer. PROCAPS S.A. started distributing its own products throughout the national territory and manufacturing customized formulas for important pharmaceutical companies, such as Wyeth, Merck, Bago, GlaxoSmithKline and Sanofi-Synthelabo.


The dynamic development of PROCAPS S.A. has resulted in the distribution of its products throughout five continents, and the subdivision of the commercial and industrial management of the company into four important businesses: Production and Distribution of Medical Prescription Pharmaceutical Products; OTC and Mass Consumption Pharmaceutical Products; Hospital Medical Supplies and Manufacturing Pharmaceutical Products, and Cosmetics and Supplement Products from customized formulas.


PROCAPS S. A. is multinational company supporting its industrial operation with a modern plant that has been granted the ISO 9001 Quality Standard and the GMP (Good Manufacturing Practices) and Seal certification. PROCAPS S.A. is a proactive organization with more than 1,000 employees, as a pharmaceutical company leader in the Andean region, and whose permanent mission is to aim its efforts towards the continuous health improvement of the worldwide community.


FORWARD LOOKING STATEMENTS: Any statements in this news release about future expectations, plans and prospects for the Company constitute forward-looking statements as defined in the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in such statements. We caution investors that actual results or business conditions may differ materially from those projected or suggested in forward-looking statements as a result of various factors and not place undue reliance on forward-looking statements.

More information about those risks and uncertainties is contained and discussed in the Company’s most recent quarterly or annual report and in the Company’s other reports filed with the Securities and Exchange Commission. The forward-looking statements represent the Company’s views as of the date of this news release and should not be relied upon to represent the Company’s views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company’s views to change, the Company disclaims any obligation to update such forward-looking statements.


DAVANAT is a registered trademark of Pro-Pharmaceuticals, Inc.


Investor Contact: Pro-Pharmaceuticals, Inc., Anthony D. Squeglia: 1.617.559.0033; squeglia@pro-pharmaceuticals.com.

Media Contact: Joanne Hogue, LVA Communications, 1.410.658.8246; joanne@lva.com.


Contact for Spanish Media: Nancy Alvarez, 1.954.684.1047; Nancyalpe24@yahoo.com